#ASH22 roundup: CSL shows two years of da­ta in $3.5M he­mo­phil­ia gene ther­a­py; Syn­dax shows 30% CR rate from March da­ta cut

NEW OR­LEANS — CSL Behring made head­lines last month af­ter the FDA gave ap­proval to the biotech for its he­mo­phil­ia B gene ther­a­py with a $3.5 mil­lion price tag. And at ASH, the biotech is re­port­ing six months’ more dura­bil­i­ty da­ta that show their treat­ment con­tin­ues to work.

The com­pa­ny’s drug was ap­proved last month af­ter a tri­al showed that, among 54 pa­tients with he­mo­phil­ia B, all but three were able to dis­con­tin­ue use of pro­phy­lax­is and re­mained free of those rou­tine treat­ments for 18 months. The com­pa­ny said that af­ter six months more of da­ta, the ef­fi­ca­cy hasn’t changed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER